IDH1 and glioma: Mutations have also been identified in isocitrate dehydrogenase 1 (IDH1) that inhibit IDH1 catalytic activity in gliomas, thereby reducing the production of α-KG, inhibiting PHD, increasing HIF-1α, and presumably, promoting tumorigenesis [33].